378 related articles for article (PubMed ID: 19664817)
1. Screening for prostate cancer remains controversial.
Neal DE; Donovan JL; Martin RM; Hamdy FC
Lancet; 2009 Oct; 374(9700):1482-3. PubMed ID: 19664817
[No Abstract] [Full Text] [Related]
2. Screening for prostate cancer remains controversial.
Stark JR; Mucci L; Rothman KJ; Adami HO
BMJ; 2009 Sep; 339():b3601. PubMed ID: 19778971
[No Abstract] [Full Text] [Related]
3. Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?
Jackson BR
Arch Pathol Lab Med; 2013 Mar; 137(3):308-9. PubMed ID: 22799565
[No Abstract] [Full Text] [Related]
4. Early detection of prostate cancer.
Taneja SS
Urol Clin North Am; 2014 May; 41(2):xi-xii. PubMed ID: 24725495
[No Abstract] [Full Text] [Related]
5. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality.
Höltl W; Lunglmayr G
Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868
[No Abstract] [Full Text] [Related]
6. Prostate specific antigen and screening for early prostate cancer.
Davidson P
N Z Med J; 2001 Apr; 114(1129):150. PubMed ID: 11400919
[No Abstract] [Full Text] [Related]
7. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?
Carroll PR; Whitson JM; Cooperberg MR
J Clin Oncol; 2011 Feb; 29(4):345-7. PubMed ID: 21189396
[No Abstract] [Full Text] [Related]
8. Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective.
Hayes JH; Barry MJ; Kantoff PW; Stahl JE
BJU Int; 2007 Sep; 100(3):486-8. PubMed ID: 17669139
[No Abstract] [Full Text] [Related]
9. Risks of PSA screening now better understood.
Peres J
J Natl Cancer Inst; 2013 Nov; 105(21):1590-2. PubMed ID: 24142893
[No Abstract] [Full Text] [Related]
10. Weighing the benefits and downsides of prostate-specific antigen screening.
Pignone M
Arch Intern Med; 2009 Sep; 169(17):1554-6. PubMed ID: 19786672
[No Abstract] [Full Text] [Related]
11. Prostate cancer. When to offer screening in the primary care setting.
Gambert SR
Geriatrics; 2001 Jan; 56(1):22-6, 29-31. PubMed ID: 11196336
[TBL] [Abstract][Full Text] [Related]
12. [PSA based screening for prostatic cancer].
Johansen TE
Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2612-4. PubMed ID: 19023357
[No Abstract] [Full Text] [Related]
13. Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer.
Kwiatkowski M; Klotz L; Hugosson J; Recker F
Eur Urol; 2012 Apr; 61(4):851-4. PubMed ID: 22285762
[No Abstract] [Full Text] [Related]
14. [Does a low PSA at 60 years old exclude the risk of developing prostate carcinoma?].
Zürcher S
Rev Med Suisse; 2014 Jun; 10(434):1316. PubMed ID: 25073308
[No Abstract] [Full Text] [Related]
15. Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians.
Kell JS
Can J Urol; 2010 Feb; 17 Suppl 1():18-25. PubMed ID: 20170597
[TBL] [Abstract][Full Text] [Related]
16. [The prostate specific antigen: what can we learn from the American experience?].
Zhao XJ
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3313-5. PubMed ID: 16409833
[No Abstract] [Full Text] [Related]
17. Prostate cancer screening.
Stattin P; Stenman UH; Riboli E; Hallmans G; Kaaks R
Lancet; 2001 Apr; 357(9263):1202-3. PubMed ID: 11332426
[No Abstract] [Full Text] [Related]
18. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
Belpomme D; Irigaray P
J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
[No Abstract] [Full Text] [Related]
19. Solving the overdiagnosis dilemma.
Esserman L; Thompson I
J Natl Cancer Inst; 2010 May; 102(9):582-3. PubMed ID: 20413743
[No Abstract] [Full Text] [Related]
20. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
Barry MJ; Mulley AJ
J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
[No Abstract] [Full Text] [Related]
[Next] [New Search]
